Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DuoGenic StemCells's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$-23.88 Mil. DuoGenic StemCells's average total tangible assets for the quarter that ended in Dec. 2025 was NT$67.59 Mil. Therefore, DuoGenic StemCells's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -35.34%.
The historical rank and industry rank for DuoGenic StemCells's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:7607'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -81.54 Med: -44.6 Max: -30.11
Current: -40.8
During the past 5 years, DuoGenic StemCells's highest Return-on-Tangible-Asset was -30.11%. The lowest was -81.54%. And the median was -44.60%.
ROCO:7607's Return-on-Tangible-Asset is ranked worse than 52.9% of 1412
companies
in the Biotechnology industry
Industry Median: -35.87
vs ROCO:7607: -40.80
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
DuoGenic StemCells Return-on-Tangible-Asset Related Terms
DuoGenic StemCells Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -35.34% mean?
DuoGenic StemCells (ROCO:7607) has a Return-on-Tangible-Asset of -35.34% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DuoGenic StemCells and its competitors. According to the industry distribution chart, DuoGenic StemCells ranks #747 out of 1412 companies in the Biotechnology industry, placing it in the top 52.9%.
Is DuoGenic StemCells' Return-on-Tangible-Asset too high?
DuoGenic StemCells' current Return-on-Tangible-Asset is -35.34%. Based on the distribution chart, DuoGenic StemCells ranks #747 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 24/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #747 out of 1412 companies for Return-on-Tangible-Asset. This places DuoGenic StemCells in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DuoGenic StemCells and its competitors. DuoGenic StemCells's current Return-on-Tangible-Asset is -35.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.51, compared to a current price of NT$13.00 — trading 74.8% below its estimated fair value. The current Return-on-Tangible-Asset is -35.34%. DuoGenic StemCells' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Return-on-Tangible-Asset is -35.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.8% below its estimated GF Value™ of NT$51.51.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Return-on-Tangible-Asset: -35.34%
GF Value™: NT$51.51 vs. price of NT$13.00 (74.8% below fair value)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
24GF Score
Get the complete analysis for ROCO:7607
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
